Peptides touted for weight loss, injury recovery, and biological rejuvenation have taken social media by storm, but independent laboratory testing reveals that over-the-counter versions sold in convenience stores may be completely fraudulent. A sample purchase of four distinct peptide vials from a shop named Mr. Green in New York City cost $376.20. The store clerk placed the vials into an unbranded paper bag without offering instructions or official verification. The acquired items included PT-141 marketed for low libido, BPC-157 marketed for muscle recovery, NAD+ marketed for cellular health, and retatrutide marketed for weight management. Subsequent scientific verification demonstrated that the contents of these vials failed to match their external labeling.
Laboratory Testing Process and Findings
The vials were submitted for rigorous chemical testing to Finnrick, an Austin-based startup that connects individual consumers and researchers with independent testing laboratories. Finnrick evaluates samples for chemical purity, dosage accuracy, heavy metals, and dangerous bacterial contaminants such as endotoxins. When the laboratory results arrived weeks later, the analytical report presented a mix of minor relief and major alarm. On one hand, the samples recorded low concentrations of heavy metals and endotoxins, indicating that they were unlikely to cause acute poisoning. On the other hand, the tests confirmed that the products contained no trace of the advertised peptides.
A precise compound comparison against chemical control standards showed that the active pharmaceutical ingredients listed on the labels were entirely missing. For instance, the vial sold as BPC-157 yielded zero presence of BPC-157. Experts noted two principal explanations for these findings: either the products were mislabeled at the time of packaging, or the fragile active molecules had degraded completely into unrecognizable byproducts. Peptides are fragile biological chains that require continuous refrigeration and careful temperature regulation. Improper transit or room-temperature storage in retail shops rapidly destroys their chemical integrity.
Statements From Testing Executives
Marco Krause, chief executive officer of the testing facility utilized by Finnrick, explained the laboratory methodology. Marco Krause stated, "What we offer is simply a label claim analysis." He clarified that the laboratory matches submitted samples against validated chemical reference standards to verify if the compound exists. Because the samples failed to produce a match, the lab could not definitively identify what mystery substances filled the vials.
Addressing the broader market trend, Finnrick chief executive officer Raphaël Mazoyer noted an increasing frequency of ineffective samples over recent months. "There are a whole bunch of labels popping up that have the same upstream vendor," Mazoyer noted. He explained that turnkey supply platforms allow virtually anyone to launch a private-label peptide business overnight. These distributors rely on identical low-quality upstream manufacturers, spreading corrupted or empty batches across dozens of different retail brands.
Widespread Inconsistencies Across Retail Vendors
This failure in product authentication is not an isolated incident. Jeff Colhoun, founder of the vendor directory Peptide Critic, conducted a parallel investigation by purchasing peptides from Smoker's World, a smoke shop located near Mr. Green. Colhoun acquired two vials of retatrutide and two vials of NAD+ manufactured by INDR Labs and submitted them for independent evaluation at Analytical Formulations, a specialized laboratory in Texas.
Analytical Formulations reported that it could not positively identify the chemical substances inside the four vials. This failure suggested that the products were either heavily contaminated or degraded beyond scientific recognition. Colhoun noted that legitimate research vendors frequently encounter corrupted batches when testing products prior to retail distribution. He warned that consumers face extreme health risks when sellers bypass batch testing entirely.
INDR Labs did not respond to inquiries regarding its product quality. Shortly after being queried, the company restricted public access to its website behind a login screen and removed public certificates of analysis. While INDR Labs previously claimed its certificates were authenticated by Vanguard Laboratory, a spokesperson for Vanguard Laboratory publicly denied issuing any documentation for the company.
A $3 Billion Unregulated Industry
Financial analysts estimate that the commercial peptide ecosystem has expanded into a market worth up to $3 billion. Public endorsements from figures such as US health secretary Robert F. Kennedy Jr. and podcaster Joe Rogan have driven massive consumer demand. While certain peptides like GLP-1 analogues and insulin are FDA-approved pharmaceuticals, most trendy peptides sold over the counter have never undergone standard clinical trials or regulatory approval pipelines.
To skirt federal drug regulations, brick-and-mortar retailers display signs stating the items are for research use only. However, these disclaimers serve primarily as legal shields for vendors rather than accurate product descriptions. Federal law prohibits selling unapproved peptides for human consumption, especially given the lack of robust clinical trial evidence supporting their health claims. Despite these legal gray areas, large telehealth firms such as Hims and Mochi are actively preparing to roll out broader peptide product lines.
Health Hazards and Expert Warnings
Fred Mills, a veteran pharmacist and executive at the Louisiana-based nonprofit Americans for Safe and Effective Medicines, expressed grave concern over retail peptide distribution. Fred Mills stated, "The FDA needs to shut down these black markets." He strongly advised consumers to avoid purchasing injectable or oral compounds from convenience stores and to consult licensed physicians before taking any peptide therapy.
Darshan Kulkarni, an attorney specializing in pharmaceutical regulatory compliance, highlighted the stark contrast between traditional drug distribution and retail smoke shops. Kulkarni pointed out that real pharmacies enforce strict verification protocols, including batch barcoding, visual inspections, and temperature-controlled logistics. Darshan Kulkarni said, "Someone selling a product at a bodega doesn't know how to do that." He emphasized that while receiving inert saline solution results in financial loss, taking adulterated or improperly synthesized compounds can be lethal, citing a case in the Bronx where a woman died after receiving a peptide injection at an unlicensed medical spa.
Enforcement Realities and Retail Operations
An FDA spokesperson confirmed that the regulatory agency issues warning letters to firms selling research-only chemicals directly to consumers or making unauthorized health claims for compounded GLP-1 drugs. However, the agency refrained from commenting on specific physical enforcement measures against brick-and-mortar storefronts like Mr. Green.
Federal law enforcement has occasionally stepped in. In South Bend, Indiana, a federal judge sentenced a man to six years in prison for illegally importing research-labeled peptides from China, which were subsequently found to be adulterated with anabolic steroids. Legal experts note that overall enforcement remains sparse due to prevailing regulatory philosophies that prioritize consumer choice over restrictive oversight. At Mr. Green, the large window menu advertising peptides was eventually removed, but a smaller menu remained beside the cash register where peptide sales continued uninterrupted.
